BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy

Nov 19, 2026

New Preclinical Findings Show TROP2 Levels May Help Predict REQORSA Treatment Response—and That Modifying TROP2 Expression May Increase Cancer Cell Sensitivity to Gene Therapy. Combined With the Roche Diagnostics Collaboration, Expanding TUSC2 Research and Advancing Clinical Programs, Genprex, Inc. (NAS DAQ: GNPX) Is Building Significant Momentum Across Its Innovative Biotechnology Platform.

AUSTIN, Texas - Nov. 19, 2026 - PRLog -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is bringing another exciting development to its growing gene therapy story with today's November 19 announcement of new preclinical data identifying TROP2 as a potential predictive biomarker for its lead investigational therapy, REQORSA® (quaratusugene ozeplasmid). Presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the research offers important new insights into how TROP2 expression may influence the response of non-small cell lung cancer (NSCLC) to REQORSA.

What makes today's announcement especially interesting is that researchers are investigating more than simply whether TROP2 can identify patients likely to respond. The new findings also suggest that changing TROP2 expression may influence how cancer cells respond to TUSC2 gene therapy, potentially opening another avenue for improving treatment sensitivity.

For Genprex investors, this represents an important addition to an increasingly sophisticated precision-oncology strategy. The company is working to combine its innovative gene therapy platform with biomarker research that could help researchers better understand treatment response and identify patients who may benefit most.

Today's Big News: TROP2 Research Reveals Another Potential Advantage for REQORSA

The November 19 announcement highlights findings from research titled "TROP2 Predicts Response to TUSC2 Gene Therapy and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment."

Researchers evaluated multiple NSCLC cell lines and patient-derived organoid models to investigate the relationship between TROP2 expression and response to TUSC2 gene delivery.

The findings were particularly noteworthy:
  • Approximately 50% of the 10 NSCLC cell lines evaluated demonstrated primary resistance to TUSC2 gene delivery.
  • Approximately 50% of the 12 patient-derived organoid models also demonstrated primary resistance.
  • Low TROP2 protein expression was consistently associated with primary resistance across multiple preclinical models.
  • Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial provided additional supporting evidence.

Perhaps the most intriguing aspect involved experiments examining whether changing TROP2 expression could influence treatment sensitivity.

Researchers introduced TROP2 into TROP2-low NSCLC cancer cells, including H460 and H1299 models. This significantly increased TUSC2-induced apoptosis, bringing the response to levels similar to cells naturally expressing higher TROP2.

This is an important scientific observation because it suggests TROP2 may have a role beyond simply identifying tumors that respond differently. Modifying its expression could potentially become another research strategy for enhancing REQORSA treatment.

The company believes these findings could help inform future patient-selection strategies and additional research into improving treatment response.

Roche Diagnostics Collaboration: A Powerful Addition to Genprex's Strategy

One of Genprex's most important strategic developments remains its collaboration with Roche Diagnostics, announced August 3.

The collaboration focuses on validating biomarker assays for non-small cell lung cancer, with particular attention to TROP2 and PTEN.

Roche brings extensive diagnostic expertise to the relationship, while Genprex contributes its developing REQORSA gene therapy platform and growing body of clinical and preclinical research.

The objective is to develop a more refined approach to identifying patients who may be more likely to benefit from REQORSA.

Previous clinical research suggested that higher TROP2 expression and lower PTEN expression were associated with longer progression-free survival in certain NSCLC patient groups.

Today's new findings add another important scientific component to this collaboration by providing additional evidence supporting the investigation of TROP2 as a potential predictive biomarker.

Genprex anticipated completing the Roche-related assay validation studies around the end of 2026, with potential incorporation into its NSCLC clinical program following successful validation.

The combination of Roche's diagnostic capabilities and Genprex's gene therapy research could become an important part of the company's precision-medicine strategy.

REQORSA: Advancing an Innovative Approach to Lung Cancer

At the center of Genprex's oncology platform is REQORSA, also known as quaratusugene ozeplasmid.

The investigational therapy is designed to deliver the TUSC2 tumor-suppressor gene into cancer cells using Genprex's proprietary ONCOPREX Delivery System, which utilizes lipid-based nanoparticles.

TUSC2 expression is reduced or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers, making it an important target for investigation.

REQORSA is designed to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression, including MAPK and mTOR signaling, cell-cycle regulation and programmed cancer-cell death.

Genprex is advancing two important clinical initiatives:

Acclaim-1: Evaluating REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced NSCLC carrying specific EGFR mutations.

Acclaim-3: Evaluating REQORSA in an extensive-stage small cell lung cancer treatment strategy.

Both programs have received FDA Fast Track designation, while the small cell lung cancer program has also received Orphan Drug Designation.

New TUSC2 Research Expands the Scientific Story

Genprex has also been generating interest through its sponsored research collaboration with Meharry Medical College.

Recent research has examined TUSC2's role in cellular resilience, mitochondrial function and biological processes associated with aging.

On November 5, the company highlighted patient-derived research involving blood samples from 11 lung cancer patients receiving REQORSA. Researchers identified changes in gene-expression patterns associated with mitochondrial adaptation, autophagy, cellular maintenance and protein quality control.

These findings add another dimension to the understanding of TUSC2's biological activity in humans and complement the company's broader scientific investigation.

Diabetes Gene Therapy Adds Another Development Opportunity

Beyond oncology, Genprex is pursuing an additional opportunity through its diabetes gene therapy program.

The approach uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.

Preclinical studies have produced encouraging findings in Type 1 and Type 2 diabetes models, including improvements in glucose control and insulin-related measures.

In August, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.

This provides another important development program as the company works toward future clinical research.

The Road Ahead: Important Catalysts for GNPX Investors

Genprex has several important developments to watch as 2026 progresses:
  • Continued investigation of TROP2 as a potential predictive biomarker for REQORSA.
  • Further research into whether TROP2 modulation can enhance treatment sensitivity.
  • Anticipated completion of Roche Diagnostics biomarker assay validation.
  • Continued advancement of the Acclaim-1 and Acclaim-3 clinical programs.
  • Additional TUSC2 research and diabetes gene therapy development.

Genprex Is Building an Intriguing Precision Gene Therapy Platform

Today's November 19 announcement adds another important milestone to Genprex's developing story. The TROP2 findings are particularly interesting because they suggest two potential opportunities: identifying patients more likely to respond to REQORSA and investigating whether changing TROP2 expression could increase treatment sensitivity.

Combined with the Roche Diagnostics collaboration, these findings strengthen the scientific foundation behind Genprex's precision-oncology ambitions.

The company's continued TUSC2 research, advancing lung cancer clinical programs and separate diabetes gene therapy initiative provide multiple areas of development to follow.

For investors watching emerging biotechnology opportunities, Genprex is building an increasingly compelling story around innovative gene therapy, strategic diagnostic collaboration and personalized cancer treatment. With today's new TROP2 findings adding another exciting dimension to REQORSA, GNPX has important scientific milestones ahead as it works to translate its research into meaningful clinical progress.

For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: [email protected]
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
CorporateAds
***@gmail.com

Photos: (Click photo to enlarge)




Source: CorporateAds

Read Full Story - BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy | More news from this source

Press release distribution by PRLog

More News

"You Are Not Special Or Better Than Us Locals Just Because You're Visiting" — People Are Sharing The 20 Worst Things About Living In A Tourism Hotspot
Nov 19, 2026
"You Are Not Special Or Better Than Us Locals Just Because You're Visiting" — People Are Sharing The 20 Worst Things About Living In A Tourism Hotspot

"If you’re trying to 'experience a city like a local' try to behave like a local and be respectful of other people’s lives." View Entire Post ›

Jetsetters Listen Up – These 36 Travel Products Will Make Your Lifestyle *Way* Easier
Nov 19, 2026
Jetsetters Listen Up – These 36 Travel Products Will Make Your Lifestyle *Way* Easier

Work smart, not hard (especially during your PTO). View Entire Post ›

Anguilla showcases diving experiences and Caribbean flavor at DEMA Show in New Orleans
Nov 19, 2026
Anguilla showcases diving experiences and Caribbean flavor at DEMA Show in New Orleans

Seeking to capture a greater share of the Caribbean’s valuable dive tourism market, the Anguilla Tourist Board showcased the destination’s underwater treasures, local flavors and welcoming hospitality at the 2026 DEMA Show, held Nov. 3-6 at the Ernest N. Morial Convention Center.

K-drama Crash 2: Fury Road – vehicular action procedural returns but offers little new
Nov 19, 2026
K-drama Crash 2: Fury Road – vehicular action procedural returns but offers little new

Lead cast: Kwak Sun-young, Lee Min-ki, Heo Sung-tae Latest Nielsen rating: 3.7 per cent The Traffic Crime Investigation (TCI) unit is back for a new season of vehicular crime-solving in the action procedural Crash 2: Fury Road. Crash first appeared in 2024, in the wake of the similar action series Taxi Driver, which at the time was already gearing up for its third season. Taxi Driver is a vigilante series, whereas Crash focuses on characters who operate within the bounds of the law. However,...

What happens when an open marriage gets messy? At 55, Michelle Tea holds nothing back
Nov 19, 2026
What happens when an open marriage gets messy? At 55, Michelle Tea holds nothing back

The prolific L.A. author and queer icon talks about marrying a monogamous man, writing about her exes without a filter and why nonmonogamy works for her — even when it hurts.

Britain's best curry houses revealed: From family-run favourites to hidden gems, these are the restaurants crowned the country's top spots - is YOUR favourite on the list?
Nov 19, 2026
Britain's best curry houses revealed: From family-run favourites to hidden gems, these are the restaurants crowned the country's top spots - is YOUR favourite on the list?

Whether you love a fiery jalfrezi, a creamy korma or an authentic Bengali feast, these are the restaurants winning over curry lovers across Britain. Has your local made the cut?

A Stay Steeped in History 
Nov 19, 2026
A Stay Steeped in History 

The remarkable 17th-century convent of Donna Camilla Savelli has been transformed into an elegant urban retreat in the heart of Trastevere, Rome The post A Stay Steeped in History  appeared first on Business Traveller.

Meet Dancing with the Stars semi-finalist Harry Shum Jr’s wife, Shelby Rabara
Nov 19, 2026
Meet Dancing with the Stars semi-finalist Harry Shum Jr’s wife, Shelby Rabara

Grey’s Anatomy actor Harry Shum Jr’s journey on Dancing with the Stars ended on Tuesday, when the 44-year-old was eliminated alongside his pro partner, Jenna Johnson, 32, despite receiving perfect scores for their semi-final routines. Judges’ scores and viewers’ votes determine eliminations, but fans rallied against Shum’s exit, calling the decision rigged. According to the US Sun, Johnson reportedly broke down in tears after the elimination. “Everyone agreed this was really unfair,” a source...

Meet Bechet Allen, Woody Allen’s daughter who defended him amid sex misconduct allegations
Nov 19, 2026
Meet Bechet Allen, Woody Allen’s daughter who defended him amid sex misconduct allegations

Woody Allen seems to be ready for the holiday season. The Annie Hall (1977) and Manhattan (1979) director, 90, was spotted enjoying some quality time in Madrid, Spain, with his wife, Soon-Yi Previn, 56, and their adopted daughter, Bechet, 27, in photographs shared by the latter on her Instagram recently. “One can consume a lot in a week,” Bechet wrote, alongside a photo of the trio enjoying a seafood meal. The couple’s other adopted daughter, 26-year-old Manzie Tio Allen, wasn’t featured in the...

Was war die Ursache für den FAA-Betriebsausfall, der Flüge in den USA am Boden hielt?
Nov 19, 2026
Was war die Ursache für den FAA-Betriebsausfall, der Flüge in den USA am Boden hielt?

Ein landesweiter FAA-Stopp in den USA führte zu Störungen tausender Flüge, nachdem Wartungsarbeiten an der Telekommunikationsanlage Netzwerkausfälle verursacht hatten. Dies zog eine Untersuchung der L3Harris-Flugsicherungsausrüstung nach sich, führte zu vermehrten Flugausfällen am Wochenende und erneuten Forderungen nach Modernisierungsmitteln. The post Was war die Ursache für den FAA-Betriebsausfall, der Flüge in den USA am Boden hielt? appeared first on Business Traveller.

Sri Lanka Tourism Concludes Successful WTM London 2026
Nov 19, 2026
Sri Lanka Tourism Concludes Successful WTM London 2026

The Sri Lanka Tourism Promotion Bureau (SLTPB) has successfully concluded its participation at World Travel Market (WTM) London 2026, which took place from 3–5 November at ExCeL London. Led by the Deputy Minister of Tourism, Hon. Prof. Ruwan Ranasinghe, the Sri Lankan delegation brought together 84 tourism operators to showcase the island’s diverse tourism offering, strengthen international trade relationships and outline its ambitious vision for the future of tourism.

Juliet Daniel changed cancer research. Students of the late Canadian scientist say she also changed lives
Nov 19, 2026
Juliet Daniel changed cancer research. Students of the late Canadian scientist say she also changed lives

Friends, students and colleagues gathered this week at McMaster University in Hamilton to celebrate Juliet Daniel, a Barbadian-Canadian professor and scientist who died April 28 at age 61. They remembered her for her accomplishments in science and for what she brought to the lives of others.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.